Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Vitamin D levels were significantly lower in patients with T2D (64.6 nmol/l vs. 74.2 nmol/l), however for both groups the mean vitamin D levels were within normal range.

Source: Characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This cross-sectional study utilizes blood samples and bone scans from previously published studies (, ).

Source: Methods.

All patients were > 50 years of age and had a relatively stable HbA1c within the last six months (± 1% based on the DCCT scale).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Associations of Circulating Osteoglycin With Bone Parameters and Metabolic Markers in Patients With Diabetes

Cross-sectional study · Frontiers in Endocrinology · 2021

Original publication title

Associations of Circulating Osteoglycin With Bone Parameters and Metabolic Markers in Patients With Diabetes

Jakob Kau Starup-Linde; Rikke Viggers; Bente Langdahl; Soeren Gregersen; Simon Lykkeboe; Aase Handberg; Peter Vestergaard

Copyright © 2021 Starup-Linde, Viggers, Langdahl, Gregersen, Lykkeboe, Handberg and Vestergaard

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Osteoglycin levels were similar in T1D and T2D patients. Osteoglycin did not correlate with glucose, HbA1c or any other biochemical marker of bone turnover. Thus, we did not find evidence supporting the existence of an osteoglycin-bone-pancreas axis.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Circulating osteoglycin may facilitate the crosstalk between bone and pancreas to empower adaptation of bone mass to whole body energy balance. We aimed to examine whether osteoglycin is associated with bone and metabolic parameters and if osteoglycin levels differ between patients with type 1 and 2 diabetes (T1D and T2D).

Source: Objective

Abstract: Design and methods

A cross-sectional study of 190 patients with diabetes mellitus and stable hemoglobin A1c (HbA1c) (97 T1D and 93 T2D) was conducted. S-osteoglycin was analyzed by ELISA. Unpaired t-tests were performed to test differences between patients with T1D and T2D and linear regression analyses were performed to investigate associations between osteoglycin, glycemic markers, bone turnover markers and characteristics.

Source: Design and methods

Abstract: Results

S-osteoglycin did not differ between patients with T1D and T2D (p=0.10). No associations were present between osteoglycin and age, gender, microvascular complications, HbA1c, or plasma glucose in T1D or T2D patients (p>0.05 for all). S-osteoglycin was not associated with levels of bone turnover markers (C-terminal cross-linked telopeptide of type-I collagen (CTX), P-procollagen type 1 amino terminal propeptide (P1NP), P-osteocalcin (OC), P-sclerostin, S-osteoprotegerin (OPG) or S-Receptor Activator of Nuclear factor Kappa beta Ligand (RANKL)) in neither T1D or T2D patients (p>0.05 for all).

Source: Results

Abstract: Conclusion

Osteoglycin levels were similar in T1D and T2D patients. Osteoglycin did not correlate with glucose, HbA1c or any other biochemical marker of bone turnover. Thus, we did not find evidence supporting the existence of an osteoglycin-bone-pancreas axis.

Source: Conclusion
Authors’ abstract

Objective

Circulating osteoglycin may facilitate the crosstalk between bone and pancreas to empower adaptation of bone mass to whole body energy balance. We aimed to examine whether osteoglycin is associated with bone and metabolic parameters and if osteoglycin levels differ between patients with type 1 and 2 diabetes (T1D and T2D).

Design and methods

A cross-sectional study of 190 patients with diabetes mellitus and stable hemoglobin A1c (HbA1c) (97 T1D and 93 T2D) was conducted. S-osteoglycin was analyzed by ELISA. Unpaired t-tests were performed to test differences between patients with T1D and T2D and linear regression analyses were performed to investigate associations between osteoglycin, glycemic markers, bone turnover markers and characteristics.

Results

S-osteoglycin did not differ between patients with T1D and T2D (p=0.10). No associations were present between osteoglycin and age, gender, microvascular complications, HbA1c, or plasma glucose in T1D or T2D patients (p>0.05 for all). S-osteoglycin was not associated with levels of bone turnover markers (C-terminal cross-linked telopeptide of type-I collagen (CTX), P-procollagen type 1 amino terminal propeptide (P1NP), P-osteocalcin (OC), P-sclerostin, S-osteoprotegerin (OPG) or S-Receptor Activator of Nuclear factor Kappa beta Ligand (RANKL)) in neither T1D or T2D patients (p>0.05 for all).

Conclusion

Osteoglycin levels were similar in T1D and T2D patients. Osteoglycin did not correlate with glucose, HbA1c or any other biochemical marker of bone turnover. Thus, we did not find evidence supporting the existence of an osteoglycin-bone-pancreas axis.

Clinical Trial Registration

ClinicalTrials.gov, identifier NCT01870557.

Publication and source details

Original title: Associations of Circulating Osteoglycin With Bone Parameters and Metabolic Markers in Patients With Diabetes

Jakob Kau Starup-Linde; Rikke Viggers; Bente Langdahl; Soeren Gregersen; Simon Lykkeboe; Aase Handberg; Peter Vestergaard

Frontiers in Endocrinology · 2021

Edited by: Giacomina Brunetti, University of Bari Aldo Moro, Italy

Reviewed by: Michaël R. Laurent, University Hospitals Leuven, Belgium; Alberto Falchetti, Istituto Auxologico Italiano (IRCCS), Italy; Daniela Merlotti, University of Siena, Italy

*Correspondence: Rikke Viggers, rikke.viggers@rn.dk; orcid.org/0000-0002-0742-9788

†These authors have contributed equally to this work and share first authorship

This article was submitted to Bone Research, a section of the journal Frontiers in Endocrinology

Copyright © 2021 Starup-Linde, Viggers, Langdahl, Gregersen, Lykkeboe, Handberg and Vestergaard2021Starup-Linde, Viggers, Langdahl, Gregersen, Lykkeboe, Handberg and Vestergaardhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Novo Nordisk10.13039/501100004191NNF18OC0052064

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:17:04.472387+00:00

DOI: 10.3389/fendo.2021.649718 · PMC8006932